CHM
Price sensitive
CHM CORE-NK Phase 1B clinical trial achieves 60% CR/CRi
Chimeric Therapeutics Ltd
No summary is available for this announcement — open the PDF to read it in full.
Sign in for more about this company, including guidance changes and other insights.
Sign in